Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

@article{Raz2006EfficacyAS,
  title={Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus},
  author={Itamar Raz and Markolf Hanefeld and Ling Xu and Christine Caria and DEBORA E. WILLIAMS-HERMAN and Hootan Khatami},
  journal={Diabetologia},
  year={2006},
  volume={49},
  pages={2564-2571}
}
The aim of this study was to assess the efficacy and safety of sitagliptin (MK-0431) as monotherapy in patients with type 2 diabetes mellitus and inadequate glycaemic control (HbA1c ≥7% and ≤10%) on exercise and diet. A total of 521 patients aged 27–76 years with a mean baseline HbA1c of 8.1% were randomised in a 1:2:2 ratio to treatment with placebo, sitagliptin 100 mg once daily, or sitagliptin 200 mg once daily, for 18 weeks. The efficacy analysis was based on an all-patients-treated… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
206 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 206 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM). Diabetes 55(Suppl 1):A462

  • P Aschner, M Kipnes, M Lunceford
  • 2006
Highly Influential
3 Excerpts

Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta - cell function after 24 weeks in patients with type 2 diabetes ( T 2 DM )

  • RN Berman, DT Finegood, SE Kahn
  • Diabetes
  • 2006

Effect of MK - 0431 , dipeptidyl peptidase IV ( DPP - IV ) inhibitor , on glycemic control after 12 weeks in patients with type 2

  • GA Herman, M Hanefeld, M Wu, X Chen, PL Zhao, PP Stein
  • DIABETES
  • 2005

Effect of MK-0431, dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes 54:A134, (Abstract

  • GA Herman, M Hanefeld, M Wu, X Chen, PL Zhao, PP Stein
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…